TY - JOUR
KW - Adult
KW - Aged
KW - Buprenorphine/adverse effects/therapeutic use
KW - Comorbidity
KW - Dose-Response Relationship, Drug
KW - Electrocardiography
KW - Epidemiologic Methods
KW - Female
KW - Heart Failure/epidemiology/physiopathology
KW - Humans
KW - Long QT Syndrome/chemically induced/epidemiology
KW - Male
KW - Methadone/adverse effects/therapeutic use
KW - Middle Aged
KW - Opiate Substitution Treatment/adverse effects/methods
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - Outcome Assessment (Health Care)/statistics & numerical data
KW - Time Factors
AU - A. Fareed
AU - D. Patil
AU - K. Scheinberg
AU - Blackinton Gale
AU - S. Vayalapalli
AU - J. Casarella
AU - K. Drexler
A1 - 
AB - The authors investigated whether patients receiving buprenorphine maintenance treatment (BMT) will have corrected QT (QTc) prolongation after taking buprenorphine for an extended period of time. They also compared QTc prolongation for patients in methadone maintenance treatment (MMT) versus BMT to determine which medication is the better option for patients with heart disease. A retrospective chart review study of 73 patients in BMT and 55 patients in MMT was performed. A linear regression model with a one-sided P value was used for data analysis. The MMT group had statistically significant prolongation of QTc compared with the BMT group (F = 3.94, P = .0001). Being diagnosed with congestive heart failure and taking methadone were the only individual variables that showed a statistically significant association with a QTc prolongation > 500 ms. The model as a whole showed statistical significance (F = 5.203, P = .007). Being diagnosed with congestive heart failure was the only individual variable that showed a statistically significant association with mortality. The model as a whole also showed statistical significance (F = 17.15, P = .000). This study supports previous findings that methadone may be associated with QTc prolongation, whereas buprenorphine may not. This study has the advantage of confirming that QTc prolongation persists in patients in MMT but not in those in BMT over an extended period of time (i.e., 5 years). Buprenorphine might a better first-line opioid maintenance treatment for patients with heart disease because buprenorphine was not associated with QTc prolongation. Patients in BMT may not need to be screened routinely for QTc prolongation.
BT - Journal of addictive diseases
C5 - Opioids & Substance Use
CP - 3
CY - England
DO - 10.1080/10550887.2013.824333
IS - 3
JF - Journal of addictive diseases
N2 - The authors investigated whether patients receiving buprenorphine maintenance treatment (BMT) will have corrected QT (QTc) prolongation after taking buprenorphine for an extended period of time. They also compared QTc prolongation for patients in methadone maintenance treatment (MMT) versus BMT to determine which medication is the better option for patients with heart disease. A retrospective chart review study of 73 patients in BMT and 55 patients in MMT was performed. A linear regression model with a one-sided P value was used for data analysis. The MMT group had statistically significant prolongation of QTc compared with the BMT group (F = 3.94, P = .0001). Being diagnosed with congestive heart failure and taking methadone were the only individual variables that showed a statistically significant association with a QTc prolongation > 500 ms. The model as a whole showed statistical significance (F = 5.203, P = .007). Being diagnosed with congestive heart failure was the only individual variable that showed a statistically significant association with mortality. The model as a whole also showed statistical significance (F = 17.15, P = .000). This study supports previous findings that methadone may be associated with QTc prolongation, whereas buprenorphine may not. This study has the advantage of confirming that QTc prolongation persists in patients in MMT but not in those in BMT over an extended period of time (i.e., 5 years). Buprenorphine might a better first-line opioid maintenance treatment for patients with heart disease because buprenorphine was not associated with QTc prolongation. Patients in BMT may not need to be screened routinely for QTc prolongation.
PP - England
PY - 2013
SN - 1545-0848; 1055-0887
SP - 244
EP - 251
EP - 
T1 - Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up
T2 - Journal of addictive diseases
TI - Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up
U1 - Opioids & Substance Use
U2 - 24074190
U3 - 10.1080/10550887.2013.824333
VL - 32
VO - 1545-0848; 1055-0887
Y1 - 2013
ER -